No definition available.

Name:	mymx_BasicWeightedAndDilutedNumberOfShare
Namespace Prefix:	mymx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	mymx_ConcentrationPercentage
Namespace Prefix:	mymx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	mymx_DescriptionOfGrantAllocated
Namespace Prefix:	mymx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	mymx_DescriptionOfOverallBudget
Namespace Prefix:	mymx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- References

No definition available.

+ Details

Name:	mymx_ExceedCurrentLiabilities
Namespace Prefix:	mymx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	mymx_SubAwardGrantRevenueEuro
Namespace Prefix:	mymx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- References

No definition available.

+ Details

Name:	mymx_SubAwardGrantRevenueUSDollar
Namespace Prefix:	mymx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- References

No definition available.

+ Details

Name:	mymx_SubAwardProjectCostUSDollar
Namespace Prefix:	mymx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- References

No definition available.

+ Details

Name:	mymx_WeightedAverageNumberOfSharesContingentlyConvertibleLoans
Namespace Prefix:	mymx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_ConvertibleNotesPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_PreferredStockSharesAuthorized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-13

+ Details

Name:	us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_FinancialInstrumentAxis=mymx_GrantRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=mymx_FirstYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=mymx_SecondYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=mymx_ThirdYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=mymx_FourthYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=mymx_FiveYearMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_PlanNameAxis=mymx_SixYearRevanueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Company and Summary of Significant Accounting Policies (Details Narrative) € in Thousands, $ in Thousands	3 Months Ended			9 Months Ended			12 Months Ended
	Sep. 30, 2023 EUR (€) shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 shares	Sep. 30, 2023 EUR (€) shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 shares	Dec. 31, 2022 EUR (€) shares
Current liabilities exceeding current assets \| €	€ 75,426			€ 75,426
Preferred stock shares authorized \| shares	5,000,000			5,000,000			5,000,000
Potentially shares issuable \| shares	830,150,223	830,150,223	793,630,391	25,750,000,000	25,750,000,000	793,630,391
Potentially shares issuable convertible loans \| shares	804,400,223	804,400,223	767,880,391
Sub award grant revenue USD \| $		$ 36			$ 440
Accumulated deficit \| €	€ (113,215)			€ (113,215)			€ (102,555)
Sub award grant revenue euro \| €	30			406
Secured convertible notes and short-term convertible notes and promissory notes \| €	€ 74,483			€ 74,483
Basic weighted and diluted \| shares	303,757,622	303,757,622	303,757,622	303,757,622	303,757,622	303,757,622
Budget description				The overall budget related to the project is US$8,850 with US$8,761 approved for the period of (May 2019 to April 2024). This includes the funds approved for the period of May 2023 to April 2024 of US$1’630	The overall budget related to the project is US$8,850 with US$8,761 approved for the period of (May 2019 to April 2024). This includes the funds approved for the period of May 2023 to April 2024 of US$1’630
Grant allocated description				The amounts mentioned in the following statements are purely related to the Company and not to the other partners in the project: The overall portion of the grant allocated to the Company is US$4,052 approved for the period of May 2019 to April 2024. This includes the funds approved for the period of May 2023 to April 2024 of US$97. In March 2023, an amendment to the contract was signed to reduce the allocated funds from ULL to the Company from US$1,328 to US$ 815, as more funds were allocated to the animal studies at ULL	The amounts mentioned in the following statements are purely related to the Company and not to the other partners in the project: The overall portion of the grant allocated to the Company is US$4,052 approved for the period of May 2019 to April 2024. This includes the funds approved for the period of May 2023 to April 2024 of US$97. In March 2023, an amendment to the contract was signed to reduce the allocated funds from ULL to the Company from US$1,328 to US$ 815, as more funds were allocated to the animal studies at ULL
Grant Revenue [Member]
Concentration risk percentage				99.00%	99.00%	100.00%	100.00%
First Year [Member]
Sub award grant revenue USD \| $					$ 599
Sub award grant revenue euro \| €				€ 542
Sub award project cost USD \| $					743
Second Year [Member]
Sub award grant revenue USD \| $					1,048
Sub award grant revenue euro \| €				909
Sub award project cost USD \| $					1,319
Third Year [Member]
Sub award grant revenue USD \| $					986
Sub award grant revenue euro \| €				899
Sub award project cost USD \| $					1,078
Fourth Year [Member]
Sub award grant revenue USD \| $					674
Sub award grant revenue euro \| €				638
Sub award project cost USD \| $					815
Five Year [Member]
Sub award grant revenue USD \| €				55
Sub award grant revenue euro \| €				47
Sub award project cost USD \| $					97
Revanue form NIH [Member]
Sub award grant revenue USD \| $					$ 3,362
Sub award grant revenue euro \| €				€ 3,035